News Image

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Provided By GlobeNewswire

Last update: Aug 12, 2024

BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025

Read more at globenewswire.com

BOUNDLESS BIO INC

NASDAQ:BOLD (12/12/2025, 5:19:22 PM)

After market: 1.16 -0.01 (-0.85%)

1.17

+0.02 (+1.74%)



Find more stocks in the Stock Screener

Follow ChartMill for more